Population differences in elastin maturation in optic nerve head tissue and astrocytes., PMID:17591890
Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas., PMID:18559498
Reciprocal regulation of LOX and LOXL2 expression during cell adhesion and terminal differentiation in epidermal keratinocytes., PMID:19394199
Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway., PMID:19625348
Lysyl oxidase activity is dysregulated during impaired alveolarization of mouse and human lungs., PMID:19797161
Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor., PMID:20439985
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment., PMID:20818376
LOXL2-mediated matrix remodeling in metastasis and mammary gland involution., PMID:21233336
The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation., PMID:22157764
LOXL1 deficiency in the lamina cribrosa as candidate susceptibility factor for a pseudoexfoliation-specific risk of glaucoma., PMID:22633114
Changes in lysyl oxidase (LOX) distribution and its decreased activity in keratoconus corneas., PMID:23041260
The role of LOX and LOXL2 in scar formation after glaucoma surgery., PMID:23821193
Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours., PMID:23828904
Tumor-secreted LOXL2 activates fibroblasts through FAK signaling., PMID:24008674
At the frontiers of lung fibrosis therapy., PMID:24022147
The Role of LOX and LOXL2 in the Pathogenesis of an Experimental Model of Choroidal Neovascularization., PMID:26258612
Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix., PMID:27221706
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial., PMID:27232579
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial., PMID:27939076
Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment., PMID:27966531
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal., PMID:28073888
Hypoxia triggers angiogenesis by increasing expression of LOX genes in 3-D culture of ASCs and ECs., PMID:28189640
Blood Vessel Basement Membrane Alterations in Human Retinal Microaneurysms During Aging., PMID:28196225
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis., PMID:28220932
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma., PMID:28246206
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma., PMID:28246207
Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease., PMID:28480218
A quick overview to the early phase clinical trials of Simtuzumab®: Are we loosing the most promising anti-fibrotic product?, PMID:29055391
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis., PMID:29990488
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease., PMID:30153359
LOXL2-A New Target in Antifibrogenic Therapy?, PMID:30986934
The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis., PMID:31008013
Abundant Expression of Lysyl Oxidase-like 2 Protein in Intrahepatic Bile Ducts of Infants With Biliary Atresia., PMID:31436671
New paradigm of B-cell biology regarding the elucidation of a new mechanism of tissue fibrosis in IgG4-related disease., PMID:31954774
Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis., PMID:32176358
LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis., PMID:32296422
LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells., PMID:32323822
Wnt signaling and Loxl2 promote aggressive osteosarcoma., PMID:32686768
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix., PMID:32749238
Significance of nuclear LOXL2 inhibition in fibroblasts and myofibroblasts in the fibrotic process of acute respiratory distress syndrome., PMID:33248114
LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling., PMID:34426599
An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies., PMID:34841699
HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer., PMID:35090965
Evaluation of Four Biomarkers in Patients Chronically Infected with Trypanosoma cruzi and Their Relationship with Disease Progression., PMID:35344933
Inhibition of lysyl oxidase‑like 2 ameliorates folic acid‑induced renal tubulointerstitial fibrosis., PMID:36168418
SPECT Imaging of Lysyl Oxidase-like 2 in a Model of Idiopathic Pulmonary Fibrosis., PMID:37307296
Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses., PMID:38057814
Translational Studies Reveal the Divergent Effects of Simtuzumab Targeting LOXL2 in Idiopathic Pulmonary Fibrosis., PMID:38873180
LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis., PMID:39145451
Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2., PMID:39173635
For research use only. Not for human or drug use.
